Global investments in life science startups and other health care oriented companies have grown exponentially over the last few years. There are a somewhat surprising number of companies willing to fork over substantial sums of money because of their belief (or perhaps just incredibly optimistic expectation) that innovative approaches to detecting and preventing disease will ultimately yield generous returns. One extremely well known behemoth actually devoted upwards of one-third of its money to fund some of these pioneering endeavors. Obviously, there are a lot of companies (maybe even the vast majority of them) that cannot risk that kind of cash in an area that, generally speaking, is still considered relatively young and uncertain. But, for those companies that can afford or are willing to gamble a bit more, funding life science startups certainly seems like a more than decent bet.
Of course, one of the driving forces behind this mounting interest is the rapid advancement and profound influence of technology. The innovation that is occurring in the medical sphere in particular is rather astounding and will continue to be so, perhaps at an even quicker pace moving forward. After all, once the ball is rolling, the momentum will just continue to carry things ahead. This tremendous progress is due, in large part, to the power of the computer coupled with an ever-increasing understanding of biochemical processes, even at the most minuscule levels.
Interestingly, the companies that are surfacing in the life science arena are becoming bolder and more ambitious. There seems to be a great deal of interest in doing far more than merely successfully curing diseases that arise, treating them in a quicker fashion, or accomplishing such at a cheaper cost. Now, much of the focus is on predicting potential outbreaks both by geographic location and disease type. The aim of this is to utilize the information that the companies are able to generate from computer modeling and analytics in order to address possible public health crises before they arise or spread in an overwhelming manner. In addition, companies are seeking to create less expensive alternatives to traditional medical tests and procedures.
In essence, the overarching goal of many of the startups that are the recipients of generous funding seems to be focused on perfecting medical predictions and preventions. Clearly, this industry goal parallels a growing consumer interest in extending life spans, improving quality of life, and reducing the possibility of pain or suffering. Usually, when industry and consumer interests collide in this ideal way, the outcome is beyond beneficial for all.